Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: A possible preselection for molecular testing?. Eur. Urol. Focus, (8)2:472--479, Elsevier BV, March 2022. [PUMA: Artificial intelligence; learning; therapy for Deep mutations; Bladder cancer; Molecular fibroblast receptor testing topic_lifescience growth factor FGFR3]
Modeling of protein conformational changes with Rosetta guided by limited experimental data. Structure, (30)8:1157--1168.e3, Elsevier BV, August 2022. [PUMA: molecular EPR dynamics; biology; integrative structure modeling; structural protein changes; topic_lifescience refinement conformational spectroscopy; Rosetta;]
NaviCenta - The disease map for placental research. Placenta, (143):12--15, Elsevier BV, November 2023. [PUMA: Networks biology Molecular integration; Omics topic_lifescience analysis; Systems interaction map;]
Personalized structural biology reveals the molecular mechanisms underlying heterogeneous epileptic phenotypes caused by de novo KCNC2 variants. Human Genetics and Genomics Advances, (3)4:100131, 2022. [PUMA: developmental variant, disease molecular encephalopathy, electrophysiology, Diseases simulations, personalized structural rare dynamics interpretation, epileptic KCNC2, and topic_lifescience DEE, variant Network, Undiagnosed biology,] URL
ProstaTrend-A multivariable prognostic RNA expression score for aggressive prostate cancer. Eur. Urol., (78)3:452--459, Elsevier BV, September 2020. [PUMA: Biomarker; cancer; Next-generation Molecular pathology; testing; Transcriptome Personalized diagnostic medicine; Prostate sequencing;]
Veratridine can bind to a site at the mouth of the channel pore at human cardiac sodium channel NaV1.5. Int. J. Mol. Sci., (23)4:2225, MDPI AG, February 2022. [PUMA: toxins; mutagenesis; docking; molecular SCN5A; voltage-gated site-directed channels; channels sodium topic_lifescience veratridine; electrophysiology; cardiac Rosetta;]